Description

Lenvanix 10 mg (Lenvatinib) The first new frontline treatment option for HCC approved in Japan Lenvatinib is a multikinase inhibitor that interrupts the pathways of VEGFR1, VEGFR2, and VEGFR3. It is used in the treatment of differentiated thyroid cancer (DTC), renal Cell Carcinoma, and Hepatocellular Carcinoma (HCC) Product Features: Product Name : Lenvanix Generic Name : Lenvatinib Formulation: Capsule Available Pack Size: 30’s Pot Available Strengths: 4 mg and 10 mg Categories: Anti-viral, Biotech Products, Drugs to treat Hepatitis Manufacturer: Beacon Pharmaceuticals Ltd. Indications Lenvatinib is a kinase inhibitor that is indicated: For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy. For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Storage Conditions Store at 25°C; excursions permitted to 15-30°C